<DOC>
	<DOCNO>NCT02807064</DOCNO>
	<brief_summary>This study aim assess efficacy supplementation mixture three bifidobacteria , allergic rhinitis..The rhinitis symptom assess validate score ( TSS ) , child age 4 17 year allergic rhinitis parietaria , mild , moderate severe , child supplement . Secondary Objectives - The effectiveness treatment VAS : - Evaluation rescue medication consumption - Evaluation quality life ( use structure questionnaire ) - Evaluation frequency school performance ( use structure questionnaire ) - Assessment sleep quality attention ( structured questionnaire ) - Satisfaction rating satisfaction parent - Evaluation asthma exacerbation child susceptible</brief_summary>
	<brief_title>Effectiveness Bifidobacteria Children Affected Seasonal Allergic Rhinitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo - control , phase 3 , 2 arm , patient select receive placebo mixture powder compose three bifidobacteria : Bifidobacterium Longum BB536 ( 3 billion unit ) + Bifidobacterium infantis M - 63 ( 1 billion unit ) Bifidobacterium breve M + -16 V ( 1 billion unit ) . The subject include study represent child age 4 17 year , seasonal allergic rhinitis moderate presenting positive skin prick test parietaria.The participation subject study base evaluation clinical history . The recruited patient divide two group accord drug used.The group A receive placebo , group B mixture bifidobacteria . The treatment perform period two month . At begin end therapy several survey carry , able compare result draw preliminary conclusion effectiveness treatment .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Children sex , age 4 17 year History seasonal allergic rhinitis mild , moderate severe , accord guideline define AIR 2013 , document recurrent episode previous year confirm skin prick test positive Written inform consent one parent legal representative Lack write informed consent least one parent legal representative Concurrent disorder infection upper low respiratory tract , nasal surgery past year , respiratory tract abnormality , immune disease Use antihistamine , nasal systemic corticosteroid , leukotriene modifier , cromolyn sodium , ongoing basis use last six week .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>